In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy
Open Access
- 1 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 143 (3) , 891-905
Abstract
Epilepsy is a major health burden, calling for new mechanistic insights and therapies. CRISPR-mediated gene editing shows promise to cure genetic pathologies, although hitherto it has mostly been applied ex vivo. Its translational potential for treating non-genetic pathologies is still unexplored. Furthermore, neurological diseases represent an important challenge for the application of CRISPR, because of the need in many cases to manipulate gene function of neurons in situ. A variant of CRISPR, CRISPRa, offers the possibility to modulate the expression of endogenous genes by directly targeting their promoters. We asked if this strategy can effectively treat acquired focal epilepsy, focusing on ion channels because their manipulation is known be effective in changing network hyperactivity and hypersynchronziation. We applied a doxycycline-inducible CRISPRa technology to increase the expression of the potassium channel gene Kcna1 (encoding Kv1.1) in mouse hippocampal excitatory neurons. CRISPRa-mediated Kv1.1 upregulation led to a substantial decrease in neuronal excitability. Continuous video-EEG telemetry showed that AAV9-mediated delivery of CRISPRa, upon doxycycline administration, decreased spontaneous generalized tonic-clonic seizures in a model of temporal lobe epilepsy, and rescued cognitive impairment and transcriptomic alterations associated with chronic epilepsy. The focal treatment minimizes concerns about off-target effects in other organs and brain areas. This study provides the proof-of-principle for a translational CRISPR-based approach to treat neurological diseases characterized by abnormal circuit excitability.Keywords
All Related Versions
Funding Information
- European Union’s Horizon 2020
- Marie Skłodowska-Curie (658418)
- Epilepsy Research Institute UK (ERUK F1701)
- Medical Research Council (MR/L01095X/1)
- Wellcome Trust (212285/Z/18/Z)
- Fondazione Cariplo (2016-0532)
- Ricerca Finalizzata Giovani Ricercatori (GR-2016-02363972)
This publication has 55 references indexed in Scilit:
- On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsyNature Communications, 2013
- Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical EpilepsyScience Translational Medicine, 2012
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortexNature Protocols, 2012
- Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effectsNature Medicine, 2012
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and explorationBriefings in Bioinformatics, 2012
- A Systems Level, Functional Genomics Analysis of Chronic EpilepsyPLOS ONE, 2011
- Gene expression analysis of the emergence of epileptiform activity after focal injection of kainic acid into mouse hippocampusEuropean Journal of Neuroscience, 2010
- Whole transcriptome analysis of the hippocampus: toward a molecular portrait of epileptogenesisBMC Genomics, 2010
- Episodic ataxia type 1 mutations differentially affect neuronal excitability and transmitter releaseDisease Models & Mechanisms, 2009